NCT05256225 2026-03-18
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
22 trialsNCT03914612 2026-03-17
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06952504 2026-03-13
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06989112 2026-03-12
DE-01
AstraZeneca
Phase 3 Recruiting
NCT07286331 2026-03-11
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT07198074 2026-03-10
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07044336 2026-03-05
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
Phase 3 Recruiting
NCT03884101 2026-02-02
LEAP-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06340568 2026-02-02
Fern-EC-01
BioNTech SE
Phase 3 Recruiting
NCT06486441 2026-01-15
ASCENT-GYN-01
Gilead Sciences
Phase 3 Active not recruiting
NCT06132958 2026-01-09
TroFuse-005
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04269200 2025-12-23
DUO-E
AstraZeneca
Phase 3 Active not recruiting
NCT03517449 2025-06-15
MK-3475-775
Eisai Inc.
Phase 3 Completed
NCT04634877 2025-06-09
KEYNOTE-B21
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03603184 2025-05-09
AtTEnd
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT06584032 2025-01-07
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed
Phase 3 Recruiting
NCT01820858 2024-04-02
EC-01
Huazhong University of Science and Technology
Phase 3 Active not recruiting
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT00411138 2023-10-11
PORTEC-3
Leiden University Medical Center
Phase 3 Unknown
NCT00006027 2020-10-22
Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00883116 2017-03-09
IXAMPLE2
R-Pharm
Phase 3 Terminated
NCT00016341 2013-04-11
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
GOG Foundation
Phase 3 Terminated